PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2034058
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2034058
Transcatheter Heart Valve Market size was valued at US$ 6,005.13 Million in 2025, expanding at a CAGR of 16.44% from 2026 to 2033.
A Transcatheter Heart Valve (THV) is a medical device intended to change a diseased heart valve with a minimally invasive approach, preventing the need for open-heart surgery. In this method, a catheter is directed through a blood vessel, often from the leg, and directed to the heart to position a replacement valve at the spot of damage. This technique, is primarily used for conditions such as aortic stenosis and is particularly appropriate for elderly or high-risk patients. This field is expanding globally due to increasing cases of valve-related heart conditions and wider approval of minimally invasive cardiac procedures. According to the World Health Organization (WHO), cardiovascular diseases remain the primary cause of death worldwide, with valvular disorders forming a substantial part of this burden. The National Institutes of Health (NIH) also notes that aging populations and improved diagnosis are increasing the identification of aortic stenosis cases requiring intervention. Government-backed healthcare systems in several countries have also begun integrating transcatheter valve procedures into standard cardiac care pathways, improving access to advanced treatment options.
Transcatheter Heart Valve Market- Market Dynamics
Technological advancements and long-term durability improvements in valve systems
Technological advancements and improvements in valve durability are playing a meaningful role in supporting the growth in the market. Advanced valves are designed to last longer, function more precisely, and adapt better to complex heart anatomies, which increases physician confidence in using catheter-based procedures instead of traditional surgery. Regulatory and healthcare bodies like, the European Medicines Agency (EMA) have supported approvals for next-generation transcatheter valve technologies, encouraging safer and more durable treatment options for patients with complex conditions. Similarly, Japan's Ministry of Health, Labour and Welfare (MHLW) has enabled organized estimation pathways for innovative cardiovascular devices, following careful integration of valve systems into clinical practice.
From industry view, Boston Scientific has been actively advancing structural heart technologies, focusing on improving valve durability, repositioning ability, and procedural precision through ongoing product development and clinical studies. Edwards Lifesciences also introduced next-generation SAPIEN valve enhancements focused on improved sealing and durability performance, helping reduce complications and supporting longer valve function.
The Global Transcatheter Heart Valve Market is segmented on the basis of Product Type, Application, Delivery Approach, Technology, End User, and Region.
The market is divided into three categories based on product type: transcatheter aortic valves, transcatheter pulmonary valves and transcatheter mitral valves. Transcatheter Aortic Valves is widely positioned as the most actively used category due to its broader clinical adoption and established procedural pathway in treating aortic stenosis. Hospitals and cardiac centers often prioritize this approach because it is supported by extensive clinical experience and clearer treatment protocols compared to newer mitral and pulmonary applications. For instance, Edwards Lifesciences has reported ongoing expansion of its SAPIEN valve platform usage across broader patient groups, reflecting stronger clinical integration in routine cardiac care. Similarly, Medtronic has continued to enhance its Evolut TAVR system, focusing on improved procedural precision and valve durability in real-world settings.
The market is differed into two types on the basis of technology: self-expanded transcatheter valve and balloon-expanded transcatheter valve. Self-expanded transcatheter valves are increasingly positioned for wider clinical use due to their adaptability in complex anatomies and ability to be repositioned during implantation, which supports better procedural control. This technology is often preferred in patients with varying vessel conditions, as it allows gradual expansion and improved sealing performance. Companies like, Abbott has continued advancement of its self-expanding Portico and related valve systems, focusing on easier delivery and improved positioning accuracy in minimally invasive procedures. Similarly, JenaValve Technology has been developing self-expanding solutions for aortic regurgitation cases, expanding treatment options for patients previously considered difficult to treat. These efforts reflect increasing clinical confidence in self-expanding systems, supporting broader procedural adoption across cardiac centers and strengthening their role in transcatheter valve-based therapies.
Transcatheter Heart Valve Market- Geographical Insights
From a global regional view, the market displays an environment, where adoption is closely associated with healthcare infrastructure strength, ageing population, and access to advanced cardiac care. Among global regions, North America is anticipated to hold an important place in the market, mainly supported by intense reimbursement systems and early access to innovative therapies. According to the U.S. Centers for Disease Control and Prevention, more than 5 million Americans are analyzed with heart valve disease each year, reflecting a large treatment-eligible population. In addition, the U.S. Food and Drug Administration (FDA) has progressively expanded approvals for transcatheter aortic valve replacement (TAVR) devices, enabling wider clinical use in different risk groups. From a public health perspective, the American Heart Association reports a notable burden of aortic stenosis, with millions of individuals affected in the country, which increases demand for valve replacement procedures. Medtronic, also continues to advance its transcatheter valve portfolio in the market through constant clinical studies and product improvements aligned with regulatory standards.
India Transcatheter Heart Valve Market- Country Insights
Regarding the market, India is gradually firming its position as it is reinforced by increasing cardiovascular disease problem, enlightening cardiac care infrastructure, and wider acceptance of minimally invasive procedures in major hospitals. The Ministry of Health and Family Welfare has highlighted cardiovascular diseases as one of the leading causes of mortality, accounting for a significant share of non-communicable disease cases in the country, which increases the need for advanced heart valve treatment options. The Indian Council of Medical Research (ICMR) has also emphasized early diagnosis and improved access to interventional cardiology services as part of national health priorities, supporting the use of catheter-based procedures in tertiary care centers. From an industry perspective, companies like Edwards Lifesciences have been escalating their existence in India by cooperating with foremost cardiac institutes such as AIIMS, where transcatheter aortic valve implantation measures are being performed for high-risk patients. Such progresses signal a steady shift to advanced structural heart care in country.
The Transcatheter Heart Valve market is formed by a mix of medical device innovators and emerging heart specialists, generating an evolving atmosphere focused on less invasive cardiac care. Healthcare contributors thru hospitals, cardiac catheterization laboratories, and specialty heart centers are gradually implementing catheter-based valve replacement methods to ease surgical risk, shorten recovery time, and improve outcomes. These solutions are brought through hospital procurement systems, clinical partnerships, and distribution networks, letting broader approach to advanced valve therapies. Constant progress is reinforced through clinical trials, regulatory approvals, physician training programs, and collaborations with research hospitals to improve valve designs. Key participants include Edwards Lifesciences, Abbott, Boston Scientific, and JenaValve Technology, among others, contributing to developments in aortic, mitral, and tricuspid valve therapies. For instance, Edwards Lifesciences expanded its SAPIEN platform usage into earlier-stage aortic stenosis patients following regulatory clearance, enabling earlier intervention strategies, while Abbott has also strengthened its structural heart portfolio through ongoing clinical studies focused on mitral valve repair technologies.
In November 2025, Anteris Technologies advanced its DurAVR transcatheter heart valve program by securing FDA approval to initiate a pivotal clinical trial, representing a key step toward commercialization in next-generation valve technologies. This development strengthens innovation pipeline, accelerates clinical validation, and supports future commercialization of advanced transcatheter heart valve technologies.
In August 2025, Medtronic received FDA approval for expanded use of its Evolut TAVR system under the Redo-TAVR indication, enabling treatment of patients with previously implanted failing transcatheter valves, strengthening long-term valve management options in structural heart care. This approval enhances treatment flexibility, improves reintervention options, and supports long-term management of transcatheter heart valve patients.